Review Article

Improving Response Rates to EGFR-Targeted Therapies for Head and Neck Squamous Cell Carcinoma: Candidate Predictive Biomarkers and Combination Treatment with Src Inhibitors

Ann Marie Egloff and Jennifer Rubin Grandis

1 Department of Otolaryngology, University of Pittsburgh, Pittsburgh, PA 15213, USA
2 Department of Pharmacology, University of Pittsburgh, Pittsburgh, PA 15213, USA
3 Eye and Ear Institute, Suite 500 200 Lothrop Street, Pittsburgh, PA 15213, USA

Correspondence should be addressed to Jennifer Rubin Grandis, jgrandis@pitt.edu

Received 14 April 2009; Accepted 17 May 2009

Recommended by Paul Harari

The epidermal growth factor receptor (EGFR)-directed antibody, cetuximab, was FDA-approved for the treatment of squamous cell carcinoma of the head and neck (SCCHN) in 2006. Additional EGFR-targeting agents in clinical development for SCCHN include other EGFR-directed antibodies, tyrosine kinase inhibitors and antisense DNA. Although the majority of SCCHN overexpress EGFR, SCCHN clinical responses to EGFR-targeting agents have been modest. Molecular predictors for SCCHN response to EGFR-targeted therapies have not been identified. However, molecular correlate studies in lung cancer and colon cancer, which have EGFR-targeted therapeutics FDA-approved for treatment, may provide insights. We describe candidate predictive markers for SCCHN response to EGFR-targeted therapies and their prevalence in SCCHN. Clinical response will likely be improved by targeted therapy combination treatments. Src family kinases mediate EGFR-dependent and -independent tumor progression pathways in many cancers including SCCHN. Several Src-targeting agents are in clinical development for solid malignancies. Molecular correlate studies for Src-targeting therapies are few and biomarkers correlated with patient response are limited. Identifying SCCHN patients who will respond to combined EGFR- and Src-targeting will require further characterization of molecular correlates. We discuss rationale for EGFR and Src co-targeting for SCCHN treatment and describe recent clinical trials implementing combined Src- and EGFR-targeted therapeutics.

Copyright © 2009 A. M. Egloff and J. R. Grandis. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

1. Introduction

Ninety-percent of head and neck cancers are squamous cell carcinomas (SCCHN) involving the mucosal surfaces of the oral cavity, pharynx, and larynx. The overall relative 5-year survival rates for cancers of the oral cavity/pharynx and larynx are estimated to be 58.3% and 64.5%, respectively [1]. Morbidities associated with SCCHN and its treatments are significant and include eating and swallowing difficulties. Targeted therapies for SCCHN are under active investigation with the goals of reducing SCCHN morbidity and mortality.

Targeted therapeutics were conceptualized as a means of exploiting specific molecular alterations associated with cancers in order to selectively kill transformed cells and spare normal, healthy tissues. Targeted therapies are anticipated to have fewer associated toxicities than standard chemotherapies, which rely predominately on increased rates of cell division to enhance killing of the tumor cells compared to healthy tissues. For tumors that are treated with radiation and/or surgery, targeted therapies delivered systemically also have the potential to eliminate micrometastases that might not be eliminated with radiation therapy (RT) and/or surgery. In addition to reduced toxicity and treatment of undetected disease, it is hypothesized that effective targeted therapy may interfere specifically with processes that the cancer is dependent upon and be more effective than conventional therapies.

The epidermal growth factor receptor (EGFR) was anticipated to be a good drug target for SCCHN treatment because the majority of SCCHN overexpress EGFR [2, 3], and higher tumor levels of EGFR are associated with poorer clinical outcomes [4, 5]. EGFR participates in SCCHN autocrine
stimulation, and overexpression of EGFR and its primary ligand in humans, transforming growth factor alpha (TGF-α), have been correlated with poor outcomes for patients receiving therapy [5]. Cetuximab (Erbitux; ImClone Systems), a chimeric monoclonal IgG1 antibody directed against EGFR, was FDA-approved for the treatment of SCCHN in combination with RT for locally or regionally advanced disease and as a monotherapy for recurrent or metastatic SCCHN patients who have failed prior platinum-based therapy [6]. In addition to antibodies directed against EGFR, small molecule tyrosine kinase inhibitors (TKI) of EGFR and EGFR antisense agents are currently under active clinical investigation for SCCHN treatment. EGFR-targeted therapeutics delivered as monotherapies for treatment of SCCHN have demonstrated fewer toxicities compared to combined modality treatment regimens but only marginal clinical response (4–10%) [7, 8]. In general responses to EGFR-targeted therapies in SCCHN clinical trials have been modest.

Improving clinical response rates will involve (1) identifying SCCHN patients who are likely to respond to EGFR-targeted therapies, (2) developing effective combinations of targeted therapies, and (3) correctly identifying patients who will respond to specific targeted agents applied alone or in combination. Our understanding of the factors contributing to targeted therapy response now extends beyond the molecular alterations of the tumor to include host genetic variation. In this review, we will summarize molecular data correlated with clinical response to EGFR-targeted therapies and discuss factors that may be considered for identifying responsive SCCHN patients. Preclinical evidence suggests that Src family kinase-targeted agents administered in combination with EGFR-targeted therapies may demonstrate improved clinical response over EGFR-targeted therapies alone. Here we also provide rationale for combining EGFR- and Src-targeted therapeutics for treatment of SCCHN, discuss published EGFR- and Src-combination treatment preclinical data, and summarize completed and ongoing clinical trials in solid tumors evaluating Src-targeted therapies in combination with EGFR-targeted therapies.

2. EGFR-Targeted Therapies for SCCHN

There are several EGFR-targeted therapies in clinical development for SCCHN, and these agents are described in Table 1. These inhibitors fall into two primary categories: EGFR-directed antibodies and EGFR tyrosine kinase inhibitors. EGFR-directed antibodies include cetuximab, nimotuzumab (YM Biosciences), panitumumab (Amgen), and zalutumumab (GenMab). EGFR-targeted tyrosine kinase inhibitors include erlotinib (Genetech and OSI Pharmaceuticals) and gefitinib (AstraZeneca). In addition to EGFR-targeted kinase inhibitors, inhibitors with broader target specificities are also in Phase II or III development for SCCHN including lapatinib (GlaxoSmithKline), which is a dual EGFR/HER2 inhibitor, and zactima (AstraZeneca), which targets VEGFR2 and RET in addition to EGFR (Table 1). More recently antisense therapy targeting EGFR has been evaluated in a Phase I clinical trial by our group [9].

Results of clinical trials for EGFR-targeted therapies cetuximab, nimotuzumab, gefitinib, and erlotinib used alone or in combination with conventional treatments for SCCHN have been reviewed by us and others and will not be described in detail here [10–12]. A Phase I study of panitumumab in combination with chemoradiotherapy involving 19-treatment-naïve patients with stage III/IV head and neck cancer reported an 87% complete response rate among the 15 evaluable patients and no grade 3 or 4 chronic toxicities [13]. A Phase I study of lapatinib in combination with chemoradiation in 35 patients with locally advanced SCCHN reported an overall response rate of 81% with radiation-associated mucositis, dermatitis, lymphopenia, and neutropenia as the most common grade 3 or 4 adverse events [14]. Our Phase I study of intratumoral delivery of EGFR antisense DNA in 17 patients with advanced, refractory SCCHN was associated with no grade 3 or 4 or dose-limiting toxicities and a clinical response rate (complete response and partial response by modified RECIST criteria) of 29% [9]. The current phase of clinical development for each of these agents is presented in Table 1.

3. Predictors of Response to EGFR-Targeted Therapies

To date, no molecular marker has been identified to correlate with SCCHN response to EGFR-targeting in patients. SCCHN tumor expression of the truncated form of EGFR, EGFR variant III (vIII), which lacks the ligand binding domain, occurs in up to 40% of SCCHN tumors and confers resistance to EGFR-targeted monoclonal antibodies in SCCHN preclinical models [15]. However, EGFR vIII expression and resistance to EGFR-targeted therapies in SCCHN patients has not been described. Molecular correlates of clinical response/nonresponse to EGFR-targeted therapies have been identified for colon and lung cancers. For example, the treatment of lung cancer with the EGFR tyrosine kinase inhibitor gefitinib demonstrated effective responses in a subset of patients whose lung cancers were subsequently found to harbor EGFR kinase activating mutations [16, 17]. Importantly, EGFR activating mutations do not appear to be frequent in SCCHN [18, 19]. Therefore, some of these molecular correlates, such as the EGFR tyrosine kinase activating mutations are not applicable to SCCHN because the frequency of these mutations is very low and will not be discussed further in this review. However, other molecular correlates of response to EGFR-targeting agents have been described for lung cancer and colorectal cancers including EGFR gene amplification, other somatic tumor mutations and patient genetic variations. These biomarkers have potential utility as predictive markers for SCCHN.

3.1. Tumor EGFR Gene Amplification. EGFR gene amplification occurs in SCCHN, and the rate of reported EGFR gene amplification in SCCHN varies substantially (Table 2). To date, there are no published reports evaluating EGFR gene amplification for association with SCCHN patient response to EGFR-targeted therapies. However, EGFR gene
### Table 1: EGFR-targeted therapies in clinical development for SCCHN.

<table>
<thead>
<tr>
<th>Agent</th>
<th>Sponsor</th>
<th>Class</th>
<th>FDA-approval</th>
<th>Clinical trial phase for SCCHN</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antigens</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cetuximab</td>
<td>C225, Erbitux</td>
<td>ImClone Systems</td>
<td>Chimeric IgG1</td>
<td>SCCHN; colorectal cancers III</td>
</tr>
<tr>
<td>Nimotuzumab</td>
<td>h-R3</td>
<td>YM Biosciences</td>
<td>Humanized IgG1</td>
<td>— IV Advanced disease; II Locally advanced disease</td>
</tr>
<tr>
<td>Panitumumab</td>
<td>ABX-EGF; Vectibix</td>
<td>Amgen</td>
<td>Fully human IgG2</td>
<td>Colorectal cancers III</td>
</tr>
<tr>
<td>Zalutumumab</td>
<td>HuMax-EGFR</td>
<td>GenMab</td>
<td>Fully human IgG1</td>
<td>— III</td>
</tr>
<tr>
<td>Tyrosine kinase inhibitors</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Erlotinib</td>
<td>Tarceva; OSI-774</td>
<td>Genetech and OSI Pharmaceuticals</td>
<td>Reversible ATP competitive</td>
<td>Lung cancer III</td>
</tr>
<tr>
<td>Gefitinib</td>
<td>ZD-1839; Iressa</td>
<td>AstraZeneca</td>
<td>Reversible ATP competitive</td>
<td>Lung cancer, relabeling limits III</td>
</tr>
<tr>
<td>Lapatinib</td>
<td>Tykerb</td>
<td>GlaxoSmithKline</td>
<td>Reversible ATP competitive dual EGFR/Her2</td>
<td>Breast cancer III</td>
</tr>
<tr>
<td>Zactima</td>
<td>ZD6474</td>
<td>AstraZeneca</td>
<td>Reversible ATP competitive VEGFR-2, EGFR and RET</td>
<td>— II</td>
</tr>
</tbody>
</table>

amplification has been reported to be positively associated with response to EGFR-directed antibody therapies in clinical trials for nonsmall lung cancers (NSCLC) and colorectal cancers. In a phase II study of 229 NSCLC patients with advanced-stage NSCLC treated with cetuximab plus chemotherapy, 76 patient tumors were evaluated for EGFR gene amplification by FISH and disease controls rate (complete response/partial response and stable disease) was found to be significantly higher in patients with FISH-positive tumors compared to FISH-negative tumors (81% versus 55%, P = .02). In this same study, median progression-free survival was also significantly longer for patients with FISH-positive tumors compared to FISH-negative tumors (6 months versus 3 months, P = .0008) [20]. Several studies have reported positive associations between EGFR gene amplification and metastatic colorectal cancer response to EGFR-directed antibodies [21–23].

EGFR gene amplification in SCCHN has been reported range between 10–58% of SCCHN (Table 2) [24–32]. The range of reported prevalence of EGFR gene amplification may be due to differences in expression by tumor anatomical site. However, several methods were used to assess EGFR gene amplification, including fluorescence in situ hybridization (FISH) and quantitative real-time polymerase-chain reaction- (Q-PCR-) based assays. In addition, different scoring methods were employed in the studies presented in Table 2, some of which included polysomy in the definition for EGFR amplification and others did not. These differences in methodologies likely contribute to the variation in reported rates of EGFR gene amplification in SCCHN. The presence of EGFR gene amplification in a substantial portion of SCCHN and the previously reported associations between EGFR gene amplification and response to EGFR-targeted therapies in other cancers suggest that EGFR gene amplification may be a predictive marker for response to EGFR-targeted therapies in SCCHN. When evaluating EGFR gene amplification for correlation with response to EGFR-targeted agents, it will be important to develop consensus definitions of EGFR gene amplification.

EGFR gene amplification has not consistently been reported to correlate with EGFR protein levels although a plausible mechanism for gene amplification without protein overexpression is lacking [25, 28–30] (Table 2). In NSCLC and colon cancers a positive association between EGFR gene amplification and protein expression has also not been consistently observed [44, 45]. Importantly, EGFR gene amplification status, but not EGFR tumor protein levels, is associated with response to EGFR-targeted therapies in NSCLC and colorectal cancers. These discrepancies likely reflect the semiquantitative and variable methods of assessing gene amplification and protein expression levels in various laboratories. The characterization of EGFR gene amplification in SCCHN patients treated with EGFR-directed antibodies and the testing of association with response to therapy will be of interest.

3.2. Tumor KRAS/HRAS Mutations. Ras proteins are small GTPases that regulate signal transduction pathways leading to cell growth, differentiation, and survival. Three Ras genes produce four Ras proteins, KraS 4A, KraS 4B, H-Ras, and N-Ras, that are more than 90% homologous but demonstrate a high degree of tumor-type mutation specificity [46]. KRAS mutations have been reported by several independent groups to be negatively associated with response to EGFR tyrosine kinase inhibitors in lung cancer and EGFR-directed antibodies in colon cancer. A metaanalysis including 17 NSCLC EGFR tyrosine kinase inhibitor clinical studies with 1008 patient tumors and 8 metastatic colorectal cancer (mCRC)
<table>
<thead>
<tr>
<th>Tumor molecular marker</th>
<th>Study/reference</th>
<th>Tumor type(s)</th>
<th>N tumors assessed</th>
<th>N tumors with molecular marker</th>
<th>Assay method</th>
<th>Positive scoring definition(s)</th>
<th>Associated with EGFR tumor levels</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EGFR gene amplification</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sheu et al., 2009 [24]</td>
<td>OSCC</td>
<td>128</td>
<td>22 (17.2%)</td>
<td>FISH</td>
<td>&gt;2.5 EGFR signals relative to Cen7 signal</td>
<td>Yes</td>
<td></td>
</tr>
<tr>
<td>Ch’ng et al., 2008 [25]</td>
<td>SCCHN</td>
<td>39</td>
<td>18 (46%)</td>
<td>FISH</td>
<td>&gt;2 EGFR signals relative to Cen7 signals or ≥15 EGFR copies per cell in ≥10% of cells</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>Chiang et al., 2008 [26]</td>
<td>OSCC</td>
<td>42</td>
<td>14 (33%)</td>
<td>Q-PCR</td>
<td>≥2 EGFR gene copies relative to LINE1 element</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>Temam et al., 2007 [27]</td>
<td>SCCHN</td>
<td>134</td>
<td>22 (17%)</td>
<td>Q-PCR (n = 134) and FISH (n = 16)</td>
<td>Q-PCR: &gt;mean + 1.96 standard deviations of normal WBC EGFR gene copy number normalized to β-globin; FISH: ≥4 gene copies in 40% of cells or gene/chromosome ratio &gt;2 or ≥15 gene copies in ≥10% of cells</td>
<td>No significant correlation between EGFR gene amplification by FISH and EGFR IHC expression</td>
<td></td>
</tr>
<tr>
<td>Chung et al., 2006 [28]</td>
<td>SCCHN</td>
<td>75</td>
<td>43 (58%)</td>
<td>FISH</td>
<td>≥4 gene copies in 40% of cells or gene/chromosome ratio &gt;2 or ≥15 gene copies in ≥10% of cells</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>Hanawa et al., 2006 [29]</td>
<td>ESCC</td>
<td>106</td>
<td>53 (50%)</td>
<td>FISH</td>
<td>EGFR signal &gt; Cen7 signal</td>
<td>Yes</td>
<td></td>
</tr>
<tr>
<td>Mrhalova et al., 2005 [30]</td>
<td>SCCHN</td>
<td>33</td>
<td>7 (21%)</td>
<td>FISH</td>
<td>≥4 EGFR signals relative to Cen7 in ≥10% of cells</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>Koyanova et al., 2005 [31]</td>
<td>Larynx cancers</td>
<td>1080</td>
<td>112 (10.4%)</td>
<td>FISH</td>
<td>≥8 EGFR signals relative to Cen7 in ≥10% of cells</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td>Freier et al., 2005 [32]</td>
<td>SCCHN</td>
<td>609</td>
<td>12.70%</td>
<td>FISH</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>KRAS mutations</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sheu et al., 2009 [24]</td>
<td>OSCC</td>
<td>29</td>
<td>2 (6.9%)</td>
<td>Sequencing</td>
<td>KRAS Q61H mutation</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td>Lea et al., 2007 [33]</td>
<td>ORAL cancers</td>
<td>122</td>
<td>5 (4%)</td>
<td>GAC database analysis</td>
<td>Somatic missense, nonsense, silent point mutations, frameshift and in-frame deletions and insertions</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td>Forbes et al., 2008 [34]</td>
<td>Oral, pharynx, larynx cancers</td>
<td>937</td>
<td>24 (3%)</td>
<td>COSMIC database</td>
<td>Datamining of published reports and somatic mutation screening from Cancer Genome Project</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td><strong>HRAS mutations</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Forbes et al., 2008 [34]</td>
<td>Oral, pharynx, larynx cancers</td>
<td>686</td>
<td>75 (10%)</td>
<td>COSMIC database</td>
<td>Datamining of published reports and somatic mutation screening from Cancer Genome Project</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td>Lea et al., 2007 [33]</td>
<td>ORAL cancers</td>
<td>170</td>
<td>19 (11%)</td>
<td>GAC database analysis</td>
<td>Somatic missense, nonsense, silent point mutations, frameshift and in-frame deletions and insertions</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td>Anderson et al., 1994 [35]</td>
<td>ORAL cancers</td>
<td>35</td>
<td>6 (22%)</td>
<td>PCR and restriction length polymorphism analysis</td>
<td>Presence of appropriately altered restriction enzyme digested DNA fragment</td>
<td>NA</td>
<td></td>
</tr>
</tbody>
</table>
PI3KCA mutations

<table>
<thead>
<tr>
<th>Study/reference</th>
<th>Tumor type(s)</th>
<th>N tumors assessed</th>
<th>N tumors with molecular marker</th>
<th>Assay method</th>
<th>Positive scoring definition(s)</th>
<th>Associated with EGFR tumor levels</th>
</tr>
</thead>
<tbody>
<tr>
<td>Murugan et al., 2008 [36]</td>
<td>SCCHN</td>
<td>37</td>
<td>2 (5%)</td>
<td>PCR and direct sequencing exons 9 and 20</td>
<td>Somatic missense, nonsense, frameshift, in-frame deletions, and insertions</td>
<td>NA</td>
</tr>
<tr>
<td>Fenic et al., 2007 [37]</td>
<td>SCCHN</td>
<td>33</td>
<td>0 (0%)</td>
<td>PCR and direct sequencing exons 9 and 20</td>
<td>Somatic missense mutations</td>
<td>NA</td>
</tr>
<tr>
<td>Qiu et al., 2006 [38]</td>
<td>SCCHN</td>
<td>38</td>
<td>4 (11%)</td>
<td>PCR and direct sequencing exons 1, 4, 5, 6, 7, 9, and 20</td>
<td>Somatic missense mutations</td>
<td>NA</td>
</tr>
<tr>
<td>Kozaki et al., 2006 [39]</td>
<td>OSCC</td>
<td>108</td>
<td>8 (7%)</td>
<td>PCR and direct sequencing exons 9 and 20</td>
<td>Somatic missense mutations</td>
<td>NA</td>
</tr>
</tbody>
</table>

PTEN mutations

<table>
<thead>
<tr>
<th>Study/reference</th>
<th>Tumor type(s)</th>
<th>N tumors assessed</th>
<th>N tumors with molecular marker</th>
<th>Assay method</th>
<th>Positive scoring definition(s)</th>
<th>Associated with EGFR tumor levels</th>
</tr>
</thead>
<tbody>
<tr>
<td>Shin et al., 2002 [40]</td>
<td>OSCC</td>
<td>86</td>
<td>4 (5%)</td>
<td>PCR and exon direct sequencing</td>
<td>Somatic missense, nonsense, silent point mutations, frameshift, in-frame deletions, and insertions</td>
<td>NA</td>
</tr>
<tr>
<td>Poetsch et al., 2002 [41]</td>
<td>SCCHN</td>
<td>52</td>
<td>7 (13%)</td>
<td>PCR and exon direct sequencing</td>
<td>Somatic missense, nonsense, frameshift, in-frame deletions, and insertions</td>
<td>NA</td>
</tr>
<tr>
<td>Mavros et al., 2002 [42]</td>
<td>OSCC</td>
<td>50</td>
<td>0 (0%)</td>
<td>PCR and exon direct sequencing</td>
<td>Somatic missense, nonsense, frameshift, in-frame deletions, and insertions</td>
<td>NA</td>
</tr>
<tr>
<td>Shao et al., 1998 [43]</td>
<td>SCCHN</td>
<td>19</td>
<td>3 (16%)</td>
<td>PCR and exon direct sequencing</td>
<td>Somatic missense, nonsense, frameshift, in-frame deletions, and insertions</td>
<td>NA</td>
</tr>
</tbody>
</table>

Squamous cell carcinoma of the head and neck (SCCHN), oral squamous cell carcinoma (OSCC), esophageal squamous cell carcinoma (ESCC), fluorescence in situ hybridization (FISH), quantitative real-time polymerase chain reaction (PCR), centromere 7 (Cen7), Genetic Alterations in Cancer (GAC) database, and the Catalogue of Somatic Mutations in Cancer (COSMIC) database.

3.3. Tumor PI3K-AKT Pathway Mutations. Phosphatidylinositol 3-kinases (PI3Ks) are heterodimeric kinases composed of regulatory and catalytic subunits that are involved in the control of cell proliferation, survival, and motility. The PI3K catalytic subunit, PI10alpha (PIK3CA) has been...
reported to be somatically mutated and activated in several
cancers including SCCHN. Activation of PIK3CA leads to
plasma membrane recruitment and activation of Akt and
downstream survival mechanisms. PIK3CA mutations have
been reported to be associated with resistance to EGFR-
targeted monoclonal antibodies in patients with metastatic
colorectal cancers (mCRC). In a study involving 110 patients
with mCRC, PIK3CA mutations were found to be sig-
nificantly associated with reduced objective response rates
following treatment with cetuximab or panitumumab \( P = .038 \)
and shorter progression-free survival \( P = .035 \) [53].
PIK3CA mutations have been reported to occur in up to 8%
of SCCHN as summarized in Table 2 [36–39].

PI3K signaling is inhibited by the activity of the
phosphatidylinositol phosphatase, PTEN. PTEN acts as a
tumor suppressor by negatively regulating the Akt signaling
pathway. PTEN mutations occur in colorectal, lung, and
head and neck cancers. Additionally, loss of PTEN expression
occurs by mechanisms including promoter methylation
and silencing or loss of heterozygosity. In SCCHN, PTEN
mutations are not common (Table 2) [40–43], and loss of
heterozygocity of PTEN has been reported to occur in
approximately 12% of SCCHN [42]. Though the association
with response to EGFR-targeted therapy in mCRC and loss of
PTEN expression does not appear to be as strongly correlated
as response and PIK3CA mutations [53], the consideration
of both tumor PTEN expression status and PIK3CA mutation
status may contribute to predicting response to EGFR-
targeted therapies in SCCHN.

3.4. EGFR Polymorphisms. Several EGFR polymorphisms
have been reported to be associated with differential response
to EGFR-targeted therapies. In lung cancer, shorter EGFR
intron 1 CA repeat polymorphism has been reported to
be associated with improved response to gefitinib in two
independent studies [54, 55]. In one study involving 70
patients with advanced NSCLC, patients with fewer than 17
CA repeats at either allele had significantly longer survival
following treatment with gefitinib than patients having both
alleles greater than 16 CA repeats \( P = .039 \) [54]. Fewer
EGFR intron 1 CA repeats were also significantly associated
with mCRC patient response to cetuximab-based treatment
in a study involving 110 mCRC patients receiving combined
cetuximab-irinotecan salvage therapy [56]. An independent
study of 139 NSCLC patients with WHO performance status
of 0 or 1 who received gefitinib reported that patients with
the EGFR haplotype of \(-216G/-191C\) had significantly
worse survival with a hazard ratio of 1.85 (95% CI: 1.09
to 3.12) after adjusting for performance status, previous
platinum treatment, skin rash, and diarrhea [57]. The EGFR
intron 1 CA repeat polymorphism has been reported to
affect EGFR basal transcription with higher transcription
rates reported in individuals with fewer CA repeats [58, 59].
Differential promoter activity has also been reported for
the two most common EGFR haplotypes at the \(-216G
\rightarrow T \text{ and } -191C \rightarrow A\) with the \(-216G/-191C\) haplotype
having lower promoter activity and mRNA expression [60,
61]. These studies, therefore, indicate that patient EGFR
polymorphisms associated with higher EGFR expression are
more likely to respond to EGFR-targeted therapies.

The presence of the EGFR K521R variant has also
been found to be associated with significantly improved
progression-free survival (PFS) and overall survival (OS) in
32 EGFR-positive mCRC patients treated with cetuximab
in combination with irinotecan [62]. Patients with the K521R
variant had significantly longer PFS than patients with wild-
type EGFR, 5.7 months versus 3.2 months, respectively, \( P = .04\), log rank test) and OS, 20.1 months versus 13.8 months,
respectively, \( P = .03 \) [62]. This EGFR variant, which
resides in the extracellular domain of EGFR, has reduced
ligand-binding, growth-stimulation, and kinase activity in
vitro for the 521K variant. These findings suggest that EGFR
polymorphisms have the potential to be correlated with
response to EGFR-targeted therapies in SCCHN.

3.5. FCyRIIa and FCyRIIIa Polymorphisms. Cetuximab,
a chimeric monoclonal IgG1 anti-EGFR antibody (Table 1),
may exert its antitumor effects via several mechanisms
including antibody-dependent cell mediated cytotoxicity
(ADCC). The fragment c (Fc) portion of IgG1 antibodies
can be recognized by the Fc gamma receptors (FCyR) on
immune effector cells to induce ADCC. Polymorphisms in
FCyRIIa have been shown to be associated with differential
response to cetuximab in mCRC patients in clinical studies
and to SCCHN cell lines in vitro [63–65]. The FCyRIIIa
polymorphism-V158F variant 158V was found to have
higher cetuximab-mediated ADCC in vitro [64, 65]. The
158V variant was also associated with longer PFS in a
study involving 69 mCRC patients treated with cetuximab
plus irinotecan [63]. These findings indicate that FCyRIII
variants may contribute to response to cetuximab in SCCHN
patients.

The ability to correctly predict which patients will
respond to which EGFR-targeted therapy will improve
clinical response and reduce treatment-associated toxicities
for these patients. However, the minority of SCCHN patients
have responded to EGFR-targeted therapies in clinical trials,
indicating that even if patients likely to respond to EGFR-
targeted therapy were identified, they would represent a small
portion of SCCHN patients. Even though the majority of
SCCHN cancers overexpress EGFR, these tumors are not
solely dependent upon EGFR activity. This is likely due to the
presence of preexisting or treatment-induced compensatory
signaling pathways. Because EGFR is activated in SCCHN
and response to EGFR-targeted therapies has been demon-
strated in clinical trials, it is reasonable to consider targeted
therapies to be used in combination with EGFR-targeted
therapeutics. Molecular signaling pathways in SCCHN that
can be activated independently of EGFR include pathways
initiated by G-protein-coupled receptors, integrins, and
other receptor tyrosine kinases. Many of these pathways
share Src family kinases (SFK) as downstream mediators of
signaling. For these reasons, SFK- and EGFR-targeted agents
for treatment of SCCHN is anticipated to have improved clinical
efficacy compared to EGFR-targeting agents alone.
Table 3: Src-targeting agents in clinical development.

<table>
<thead>
<tr>
<th>Agent</th>
<th>Sponsor</th>
<th>Target(s)</th>
<th>SFKs targeted (IC50)</th>
<th>Target site</th>
<th>Irreversible</th>
<th>Solid cancers in phase II or III clinical study*</th>
<th>FDA approval (Date)</th>
<th>SCCHN clinical trial phase</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dasatinib</td>
<td>BMS-354825</td>
<td>Src; Abl; c-Kit; PDGFR; others</td>
<td>ATP-binding</td>
<td>No</td>
<td>SCLC, NSCLC, breast, colorectal, head and neck, liver, melanoma, ovarian, pancreatic, sarcoma</td>
<td>Chronic myeloid leukemia (June 2006)</td>
<td>II</td>
<td></td>
</tr>
<tr>
<td>AZD0530</td>
<td>AstraZeneca</td>
<td>Src; Abl</td>
<td>ATP-binding</td>
<td>No</td>
<td>SCLC, NSCLC, breast, colorectal, head and neck, melanoma, osteosarcoma, ovarian, pancreatic, prostate</td>
<td>—</td>
<td>—</td>
<td></td>
</tr>
<tr>
<td>Bosutinib</td>
<td>SKI-606</td>
<td>Src; Abl</td>
<td>ATP-binding</td>
<td>No</td>
<td>Breast</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>KX01</td>
<td>KX2-391</td>
<td>Src</td>
<td>Peptide-binding</td>
<td>No</td>
<td>(phase I)</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>XL999</td>
<td>Exelixis</td>
<td>Src, VEGFR, PDGFR, FGFR, FLT-3, others</td>
<td>ATP-binding</td>
<td>No</td>
<td>NSCLC, colorectal, kidney, ovarian</td>
<td>—</td>
<td>—</td>
<td></td>
</tr>
</tbody>
</table>

*ClinicalTrials.gov solid tumors.

4. Src Family Kinases in SCCHN

Eight Src nonreceptor protein tyrosine kinase family members are expressed in humans: c-Src, Blk, Fgr, Fyn, Hck, Lck, Lyn, and c-Yes. c-Src, Fyn, Lyn, and c-Yes are broadly expressed, while Blk, Fgr, Hck, and Lck expression is primarily restricted to hematopoietic cells [66]. Src kinases have been implicated in normal cellular functions including cell adhesion, migration, angiogenesis, survival, proliferation, and differentiation [67, 68]. When these processes are inappropriately regulated, they can contribute to tumorigenesis, tumor progression and metastases. In SCCHN models, Src kinases are activated in response to EGFR stimulation [69], associate with EGFR [69], and have reduced activity following EGFR inhibition in vitro [70]. Src kinases are also upstream activators of EGFR and other receptor tyrosine kinases (RTKs). Following G-protein-coupled receptor (GPCR) stimulation, Src kinases are activated, resulting in the release of RTK ligands [71, 72]. In addition to RTKs and GPCRs, Src kinases are also activated by integrins in SCCHN [73]. Src kinases, therefore, are involved in the autocrine/paracrine stimulation of SCCHN and mediate EGFR-dependent and EGFR-independent signaling events.

Of the Src family kinases (SFK), c-Src is the most studied and most often implicated in cancer. Elevated c-Src protein and/or kinase activity has been reported for cancers of the lung, colon, breast, ovary, and pancreas in addition to head and neck cancers [68, 74]. c-Src is rarely mutated in cancer [74–76]. Therefore, increased activity of upstream signaling components and/or decreased activity of c-Src negative regulators are likely causes of c-Src activation observed in many epithelial cancers.

The expression and activation of specific SFK in SCCHN are less well understood. The SFK c-Src, Fyn, Lyn, and c-Yes are activated in SCCHN cell lines in vitro following stimulation with the EGFR ligand TGF-α [69], and these SFK likely play roles in SCCHN. At least one group has reported differential response of SFK to integrin β6 signaling following simulation with fibronectin, the integrin β6 ligand, in oral squamous cell carcinoma cell lines. Integrin β6, which is neoexpressed in SCCHN, has been found to activate Fyn but not c-Src or c-Yes in SCCHN upon ligation with fibronectin, leading to Fyn-dependent activation of the Raf-ERK/MAPK pathway [73]. The murine knock-out models of specific SFK provide insights into the different roles of the individual SFK. The functions of some of the SFKs are redundant, at least regarding mouse development, as evidenced by lack of phenotype for single knock-out models of c-yes, hck, c-fgr, and blk [66]. The single knock-out murine models of lyn and lck had immune impairments, fyn knock-out mice exhibited defective brain development and impaired memory and immune functions, and c-src...
null mice developed a bone remodeling disease with excess accumulation of bone [66]. Therefore, some functions are likely shared between the four SFKs with a subset of functions that may be unique to selective SFK.

5. Src Family Kinases in SCCHN Invasion and Progression

Mortality from SCCHN is usually associated with tumor invasion and locoregional metastases. The major site of SCCHN metastases is locoregional lymph nodes, and presence of neck lymph node metastases is universally accepted as the most important prognostic indicator for SCCHN. The development of metastases requires that cells move from the primary tumor and invade surrounding tissues. Invasion by tumor cells is preceded by the loss of cell adhesion and the gain of mesenchymal features in a process similar to events that occur in development termed epithelial-mesenchymal transition (EMT) [77]. EMT is accompanied by the loss of E-cadherin, which is a principal component of cell adhesion complexes, and the gain of mesenchymal characteristics including expression of vimentin [77].

The activation of Src kinases has been shown to be involved in EMT in cancer [78]. More recently, a study evaluating 50 primary SCCHN tumors for activated phospho-Src (P-Src), E-cadherin, and vimentin expression by immunohistochemical staining found increased P-Src, decreased E-cadherin, and presence of vimentin expression in SCCHN tumors to be significantly associated (P < .05) with morphologies associated with aggressive cancers including penetrating invasive fronts, poor or sarcomatoid differentiation, and lymph node metastases [79]. It is important to note that the P-Src antibody used in this study recognizes several activated SFKs and is not specific for P-c-Src. In addition to studies in SCCHN tumors, preclinical studies indicate that SFKs are involved in SCCHN migration and invasion. Our group found that blockade using an Src-specific inhibitor A-419259 resulted in decreased invasion and growth of SCCHN cell lines in vitro following stimulation with a GPCR ligand, gastrin-releasing peptide [72]. An independent group found that blockage using an Src-specific inhibitor (Table 3), while AZD0530 and bosutinib are dual SFK/Abl inhibitors. Dasatinib, which was FDA-approved for treatment of nonsolid tumors in June 2008, and AZD0530 are in Phase II clinical trials for SCCHN. Bosutinib and XL999 are in Phase II clinical trials for other cancers (Table 3). However, XL999, which inhibits VEGFR, PDGFR and FGFR in addition to Src kinases, was associated with serious cardiovascular toxicities in Phase I and II clinical trials [82–84]. Exelixis suspended new patient enrollment in the ongoing XL999 clinical trials in November 2006. A new addition to Src inhibitors in clinical development includes the c-Src substrate competitive inhibitor, KX01, which is currently being tested in phase I clinical trials. KX01 is exquisitely specific for c-Src whereas other Src-targeting agents inhibit other SFK in addition to c-Src [85–87]. To date there are no reports of Src-targeted therapeutics in SCCHN clinical trials or molecular predictors of response to Src-targeted therapies in patients with solid malignancies.

6. Src-Targeting Agents in Clinical Development

Several small molecule inhibitors of c-Src and SFK are currently in clinical development for solid tumors including dasatinib (Sprycel, BMS), AZD0530 (AstraZeneca), bosutinib (SKI-606; Wyeth), XL999 (Exelixis), and KX01 (Kinex) (Table 3). All of these inhibitors are reversible inhibitors, and all except KX01 are ATP-competitive inhibitors (Table 3). These inhibitors differ primarily in their target specificities. Dasatinib and XL999 target several known kinases in addition to SFK (Table 3), while AZD0530 and bosutinib are dual SFK/Abl inhibitors. Dasatinib, which was FDA-approved for treatment of nonsolid tumors in June 2008, and AZD0530 are in Phase II clinical trials for SCCHN. Bosutinib and XL999 are in Phase II clinical trials for other cancers (Table 3). However, XL999, which inhibits VEGFR, PDGFR and FGFR in addition to Src kinases, was associated with serious cardiovascular toxicities in Phase I and II clinical trials [82–84]. Exelixis suspended new patient enrollment in the ongoing XL999 clinical trials in November 2006. A new addition to Src inhibitors in clinical development includes the c-Src substrate competitive inhibitor, KX01, which is currently being tested in phase I clinical trials. KX01 is exquisitely specific for c-Src whereas other Src-targeting agents inhibit other SFK in addition to c-Src [85–87]. To date there are no reports of Src-targeted therapeutics in SCCHN clinical trials or molecular predictors of response to Src-targeted therapies in patients with solid malignancies.

7. Cotargeting of EGFR and Src Family Kinases in Patients

Combining EGFR- and Src-targeted therapies for SCCHN is supported by results from preclinical studies. Our group reported that combined AZD0530 and gefitinib treatment of SCCHN cell lines in vitro resulted in significantly reduced cell growth and invasion compared to single agent treatments [88]. De novo and acquired resistance to cetuximab are means by which SCCHN patients fail therapy.

SCCHN and NSCLC preclinical models selected for resistance to cetuximab in vitro have been reported to have high levels of activated SFK and to have decreased PI3K/Akt activity following dasatinib treatment [89]. Interestingly, these cetuximab resistant cells were found to be resensitized to cetuximab following treatment with dasatinib [89]. These data in addition to our current understanding that many EGFR-independent cell signaling pathways, including GPCR- and integrin-initiated pathways, are modulated at least in part by SFK provide the rationale for the combined targeting of EGFR and SFK for treatment of SCCHN.

To date, there are no published reports of combined EGFR- and Src-targeted therapies for treatment of patients with solid tumors. Three clinical trials combining EGFR- and Src-targeted therapies for upper aerodigestive cancers are currently ongoing. A Phase I trial combining dasatinib with erlotinib in patients with recurrent NSCLC is ongoing at the H. Lee Moffitt Cancer Center and Research Institute (NCT00444015, ClinicalTrials.gov). A Phase I/II study in NSCLC also combining dasatinib with erlotinib is ongoing at M.D. Anderson Cancer Center (NCT00826449, ClinicalTrials.gov). Our group will soon open a Phase 0 biomarker modulation study combining erlotinib with dasatinib for
patients with SCCHN or NSCLC (NCT00779389, Clinical-Trials.gov). Results from these trials are not yet available. Our group recently completed a Phase I trial combining cetuximab with dasatinib for treatment of advanced solid malignancies (NCT00388427, ClinicalTrials.gov). Seventeen of 25 patients enrolled in our Phase I study were evaluable for response, and 9 had stable disease while headache was a primary toxicity [90]. We have evaluated molecular correlates in these patients and found that P-SFK levels in peripheral blood mononuclear cells were transiently reduced following daily dasatinib dosing (unpublished data). In addition, we found that EGFR, TGF-α, and amphiregulin plasma levels were altered following treatment (unpublished data). A Phase II study combining dasatinib and cetuximab for treating SCCHN patients is planned at the University of Pittsburgh Cancer Institute. Results from molecular correlate studies from this trial and others will be of great importance as the SCCHN medical and research communities work to identify predictive molecular markers of response to these therapies.

8. Summary and Future Directions

Despite the ubiquitous expression of EGFR in SCCHN, clinical responses to EGFR targeting agents, particularly, when administered as single agents, has been modest. Cetuximab was FDA-approved in 2006 for the treatment of newly diagnosed SCCHN in combination with radiation and recently extended to the recurrent/metastatic population in combination with chemoradiotherapy. However, in most of these trials, expression levels of EGFR in the tumor have not correlated with response to cetuximab and no single biomarker to date in baseline tissue has been proven to predict response to EGFR targeting agents. Comprehensive genomic and proteomic studies of baseline tissue are required in the context of clinical trials to begin to identify potential markers of clinical activity. Since EGFR signaling involves intracellular interactions with other oncogenic pathways in SCCHN preclinical models, it is plausible that cotargeting of EGFR in conjunction with blockade of these pathways may be beneficial. Src family kinases represent a potential pathway for targeting, especially given the FDA-approval of the Src kinase inhibitor dasatinib for hematopoietic malignancies. Studies are underway to test this hypothesis in SCCHN patients. Challenges include: (1) the difficulty of testing antiinvasive/antimetastatic agents in clinical trial settings, and (2) the possibility that RECIST criteria may not reflect decreased tumor proliferation, metabolism, or increased apoptosis as evidence by studies that have incorporated PET tracers. More relevant endpoints in EGFR/Src-targeted trials than tumor shrinkage may include time to progression or overall survival. This may be especially relevant for locoregional recurrence/metastases in SCCHN [91].

Acknowledgment

The second author was supported by Grants no. P50 CA097190-06 and no. R01 CA77308.

References


Submit your manuscripts at http://www.hindawi.com